Healthy Volunteers, Human Metapneumovirus, Respiratory Syncytial Virus Infection
Conditions
Brief summary
The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population.
Detailed description
Study duration per participant: 12 months for the Sentinel and Main Cohorts and 24 months overall for the subset of participants enrolled in the Booster Cohort. Treatment Duration: Sentinel Cohort: 1 IM injection. Participants will be followed for 12 months post-vaccination. Main Cohort: 1 IM injection. Participants will be followed for 12 months post-vaccination. Booster Cohort: 1 IM injection 12 months after the primary vaccination (Main Cohort). Participants will be followed for 12 months after administration of the booster dose.
Interventions
BIOLOGICALRSV/hMPV vaccine candidate Dose L
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
BIOLOGICALRSV/hMPV vaccine candidate Dose A
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
BIOLOGICALRSV/hMPV vaccine candidate Dose B
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
BIOLOGICALPlacebo
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Sponsors
Sanofi Pasteur, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Sentinel, Main, and Booster Cohorts: observer-blind; for safety evaluation purposes, the Sponsor will be unblinded * Investigators, laboratory personnel, and participants will be blinded * Sponsor study staff and study staff preparing/administering the study interventions will be unblinded
Intervention model description
Dose-escalation (Phase I, sentinel cohort), parallel (Phase IIa, main cohort), multi-center
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Aged 60 years or older on the day of inclusion * A female participant is eligible to participate if she is not pregnant or breastfeeding and is of non-childbearing potential. * Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion Note: Participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: * Any screening laboratory parameter with laboratory abnormalities deemed clinically significant by the investigator * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy. Persons living with stable human immunodeficiency virus (HIV) are not excluded * Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID-19) vaccine * History of RSV and/or hMPV-associated illness, diagnosed clinically, serologically, or microbiologically in the last 12 months * Previous history of myocarditis, pericarditis, and/or myopericarditis * Screening electrocardiogram that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results * Thrombocytopenia or bleeding disorder, contraindicating intramuscular (IM) injection based on investigator's judgment * Receipt of anticoagulants in the 3 weeks preceding inclusion * Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion * Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion * History of acute infection symptoms or a positive severe acute respiratory syndrome coronavirus reverse transcription polymerase chain reaction (SARS-CoV-2 RT-PCR) or antigen test in the 10 days prior to the visit. A prospective participant should not be included in the study until the condition has resolved * Receipt of any vaccine other than mRNA vaccine in the 4 weeks preceding any study intervention administration or planned receipt of any vaccine other than mRNA vaccine in the 4 weeks following any study intervention administration * Receipt of any mRNA vaccine in the 60 days preceding any study intervention administration or planned receipt of any mRNA vaccine in the 60 days following any study intervention administration * Previous vaccination against RSV and/or hMPV (with a licensed or investigational vaccine either as a monovalent vaccine or any combination of the antigens) * Receipt of immune globulins, blood, or blood-derived products in the past 3 months * Participation at the time of study enrollment (or in the 4 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of unsolicited systemic immediate adverse events (AEs) | Within 30 minutes after primary vaccination | Number of participants experiencing immediate an immediate unsolicited systemic adverse event |
| Presence of solicited injection site or systemic reactions | Within 7 days after primary vaccination | Number of participants reporting: * injection site reactions: pain, erythema and swelling * systemic reactions: fever, headache, fatigue, myalgia, arthralgia and chills |
| Presence of unsolicited AEs | Within 28 days after vaccination | Number of participants experiencing unsolicited AEs |
| Presence of medically attended adverse events (MAAEs) | Up to 6 months after primary injection | Number of participants experiencing MAAEs |
| Presence of serious adverse events (SAEs) | Up to 6 months after primary injection | Number of participants experiencing SAEs |
| Presence of adverse events of special interest (AESIs) | Up to 6 months after primary injection | Number of participants experiencing AESIs |
| Presence of related SAEs | Throughout study (approximately 24 months) | Number of participants experiencing related SAEs |
| Presence of related AESIs | Throughout study (approximately 24 months) | Number of participants experiencing related AESIs |
| Presence of fatal SAEs | Throughout study (approximately 24 months) | Number of participants experiencing fatal SAEs |
| Presence of out-of-range biological test results | Within 7 days after vaccination | Number of participants with biological safety assessment values out of normal range (as per the laboratory performing the test, including shift from baseline values) |
| RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- primary vaccination (D29) in Phase IIa (Main/Booster Cohort) | Day 1 and Day 29 | RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- primary vaccination (D29) |
| hMPV serum nAb titers at pre-vaccination (D01), 28 days post-primary vaccination (D29) in Phase IIa (Main/Booster Cohort) | Day 1 and Day 29 | hMPV serum nAb titers at pre-vaccination (D01), 28 days post-primary vaccination (D29) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post-primary vaccination (D29) | Day 1 and Day 29 | RSV-A serum nAb titers at pre-vaccination (D01), 28 days (D29) post-primary vaccination |
| RSV-B serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post-primary vaccination (D29) | Day 1 and Day 29 | RSV-B serum nAb titers at pre-vaccination (D01), 28 days (D29) post-primary vaccination |
| hMPV serum nAb titers at pre vaccination (D01), 28 days post-primary vaccination (D29) | Day 1 and Day 29 | hMPV serum nAb titers at pre-vaccination (D01), 28 days (D29) post-primary vaccination |
| RSV A serum nAb titers at pre-vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | RSV A serum nAb titers at pre-vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination |
| RSV B serum nAb titers at pre-vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | RSV B serum nAb titers at pre-vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination |
| RSV A serum anti-F immunoglobulin G (IgG) antibody (Ab) titers at pre-vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | RSV A serum anti-F immunoglobulin G (IgG) antibody (Ab) titers at pre-vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination |
| hMPV A serum nAb titers at pre vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | hMPV A serum nAb titers at pre vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination |
| hMPV A serum anti-F IgG Ab titers at pre vaccination (D01), 28 days (D29), 3, 6, 9 and 12 months post-primary vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | hMPV A serum anti-F IgG Ab titers at pre vaccination (D01), 28 days (D29), 3 months (D91), and 6 months (D181) post vaccination |
| RSV A serum nAb titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post-booster vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | RSV A serum nAb titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post-booster vaccination |
| RSV B serum nAb titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post-booster vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | RSV B serum nAb titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post-booster vaccination |
| RSV A serum anti-F IgG Ab titers at pre-booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post- booster vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | RSV A serum anti-F IgG Ab titers at pre-booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post- booster vaccination |
| hMPV A serum nAb titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post booster vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | hMPV A serum nAb titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post-booster vaccination |
| hMPV serum anti-F IgG Ab titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post booster vaccination | Day 1, Day 29, Month 3, Month 6, Month 9 and Month 12 | hMPV serum anti-F IgG Ab titers at pre booster vaccination (D01), 28 days (D29), and 3, 6, 9, and 12 months post- booster vaccination |
Countries
Puerto Rico, United States
Outcome results
None listed